Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

Trial Details

NCT ID

NCT05922501

Phase

PHASE2

Sponsor

Massachusetts General Hospital

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Isatuximab
Belantamab mafodotin
Pomalidomide
Dexamethasone

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977
Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medica…
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix A).
Age ≥ 18 years
Measurable disease of multiple myeloma as defined by at least one of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →